Skip to main content
SpringerLink
Log in
Book cover

Cardiovascular Disease in AIDS pp 143–153Cite as

Guidelines for the Prevention of Cardiovascular Risk in HIV-Infected Patients Treated with Antiretroviral Drugs

  • Chapter

  • 301 Accesses

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   159.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Palella FJ, Delaney KM, Mooreman AC et al (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338:853–860

    Article  PubMed  Google Scholar 

  2. Dubè MP, Sattler FR (1998) Metabolic complications of antiretroviral therapies. AIDS Clinical Care 10:41–44

    PubMed  Google Scholar 

  3. Sullivan AK, Nelson MR (1997) Marked hyperlipidaemia on ritonavir. AIDS 11:938–939

    Article  PubMed  CAS  Google Scholar 

  4. Hengel RL, Watts NB, Lennox JL (1997) Benign symmetric lipomatosis associated with protease inhibitors. Lancet 350:1596

    Article  PubMed  CAS  Google Scholar 

  5. Miller KD, Jones E, Yanovski JA et al (1998) Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 351:871–875

    PubMed  CAS  Google Scholar 

  6. Carr A, Samaras K, Burton S et al (1998) A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12:F51–F58

    Article  PubMed  CAS  Google Scholar 

  7. Lo JC, Mulligan K, Tai VW et al (1998) “Buffalo hump” in men with HIV-infection. Lancet 351:867–870

    PubMed  CAS  Google Scholar 

  8. Carr A, Samaras K, Chisholm DJ, Cooper DA (1998) Pathogenesis of HIV-1-protease inhibitor-associated peripheral liopdystrophy, hyperlipidemia, and insulin resistance. Lancet 352:1881–1883

    Article  Google Scholar 

  9. Rosenberg HE, Mulder J, Sepkowitz K et al (1998) “Protease-paunch” in HIV+ persons receiving protease inhibitor therapy: incidence, risks and endocrinologic evaluation. Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, February 1998, abstract 408

    Google Scholar 

  10. Kotler DP, Rosenbaum KB, Wang J et al (1998) Alterations in body fat distribution in HIV-infected men and women. Twelfth World AIDS Conference, Geneva, Switzerland, June–July 1998, abstract 32173

    Google Scholar 

  11. Engelson ES, Kotler DP, Tan YX et al (1998) Altered body fat distribution in HIV infection: regional body composition measurements by whole body MRI and DXA scans. Twelfth World AIDS Conference, Geneva, Switzerland, June–July 1998, abstract 32181

    Google Scholar 

  12. Boyle BA (1999) Lipodystrophy: A new phenomeneon? AIDS Reader 9:15–17

    PubMed  CAS  Google Scholar 

  13. Gervasoni C, Ridolfo AL, Trifirò G et al (1999) Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 13:465–471

    Article  PubMed  CAS  Google Scholar 

  14. Bernasconi E (1999) Metabolic effects of protease inhibitor therapy. AIDS Reader 9:254–269

    PubMed  CAS  Google Scholar 

  15. Scevola D, Di Matteo A, Uberti F et al (2000) Reversal of cachexia in patients treated with potent antiretroviral therapy. AIDS Reader 10:365–375

    PubMed  CAS  Google Scholar 

  16. Henry K, Zackin R, Dube M et al (2001) Metabolic status and cardiovascular disease risk for a cohort of HIV-1-infected persons durably suppressed on an indinavir-containing regimen(ACTG 372A). Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections. February 4–8, 2001, Chicago, Illinois, abstract 656

    Google Scholar 

  17. Adams PF, Marano MA (1995) Current estimates from the National Health Interview Survey, 1994, National Center for Health Statistics. Vital Health Statistics 10:193

    Google Scholar 

  18. Anonymous (1999) Department of Health and Human Services, Healthy People 2010, Draft for Public Comment

    Google Scholar 

  19. Henry K, Melroe H, Huebesh J et al (1999) Experience with the National Cholesterol Education Program (NCEP) guidelines for the identification and treatment of protease inhibitor related lipid abnormalities: results of a prospective study. Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, 1999, abstract 671

    Google Scholar 

  20. Grunfeld C, Feingold KR (1992) Metabolic disturbances and wasting in the acquired immunodeficency syndrome. N Engl J Med 5:329–337

    Google Scholar 

  21. Lonergan JT, Havlir D, Barber E, Mathews WC (2001) Incidence and outcome of hyperlactatemia associated with clinical manifestations in HIV-infected adults receiving NRTI-containing regimens. Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections, February 4–8, 2001, Chicago, Illinois, abstract 624

    Google Scholar 

  22. Scevola D, Bottari G, Oberto L, Faggi A (1996) AIDS cachexia: basics and treatment. In: Ruf B, Pohle HD, Goebel FD, L’age M (eds) HIV-Infektion, Pathogenese, Diagnostik und Therapie. Socio-Medico Verlag, Graefelfing, pp 281–327

    Google Scholar 

  23. Melchior JC, Salmon D, Rigaud D et al (1991) Resting energy expenditure is increased in stable, malnourished HIV-infected patients. Am J Clin Nutr 53:437–441

    PubMed  CAS  Google Scholar 

  24. Grunfeld C, Pang M, Shimizu L et al (1992) Resting energy expenditure, caloric intake and short-term weight change in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Am J Clin Nutr 55:455–460

    PubMed  CAS  Google Scholar 

  25. Shevitz AH (2000) Resting energy expenditure in the HAART era. AIDS Reader 10:539–544

    PubMed  CAS  Google Scholar 

  26. WHO (1986) Working group on the use and interpretation of anthropometric indicators of nutritional status. Bull WHO 64:929–941

    Google Scholar 

  27. Kotler DP, Rosenbaum K, Wang J, Pearson RN (1999) Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr Hum Retrovirol 20:228–237

    PubMed  CAS  Google Scholar 

  28. Scevola D (1993) La cachessia nelle malattie infettive e neoplastiche. Edizioni Medico Scientifiche, Pavia

    Google Scholar 

  29. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–2497

    Google Scholar 

  30. Scevola D, Di Matteo A, Lanzarini P et al (2003) Effect of exercise and strength training on cardiovascular status in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 17(S1):S123–S129

    PubMed  Google Scholar 

  31. Volberding PA, Murphy RL, Barbaro G et al (2003) The Pavia consensus statement. AIDS 17(S1):S170–S179

    PubMed  Google Scholar 

  32. Dubé MP, Stein JH, Aberg JA et al (2003) Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS clinical trials group. Clin Inf Dis 37:613–627

    Google Scholar 

  33. Barrios A, Blanco F, GarcÌa-Benayas T et al (2002) Effect of dietary intervention on highly active antiretroviral therapy-related dyslipemia. AIDS 16:2079–2081

    Article  PubMed  Google Scholar 

  34. Von Roenn JH (1994) Management of HIV-related body weight loss. Drugs 47:774–783

    Google Scholar 

  35. Scevola D, Bottari G, Zambelli A et al (1992) Trattamento dietetico ed ormonale dei deficit nutrizionali nell’AIDS. Clin Dietol 19:127–140

    Google Scholar 

  36. Tisdale M, Beck SA (1991) Inhibition of tumour induced lipolysis in vitro and cachexia and tumour growth in vivo by eicosapentaenoic acid. Biochem Pharmacol 41:103–107

    Article  PubMed  CAS  Google Scholar 

  37. Kardinal CG, Loprinzi CL, Schaid DJ et al (1990) A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 65:2657–2662

    PubMed  CAS  Google Scholar 

  38. Scevola D, Zambelli A, Bottari G et al (1991) Appetite stimulation and body weight gain with medroxyprogesterone acetate in AIDS anorexia and cachexia. Farmaci e Terapia 3:77–83

    Google Scholar 

  39. Scevola D, Parazzini F, Negri C, Moroni M (1995) Efficacy and safety of high-dose MPA treatment of AIDS cachexia: the Italian multicentre study. Fourth Congress of the European Association for Palliative Care. Barcelona, December 6–9, 1995, abstracts book, pp 443–447

    Google Scholar 

  40. Scevola D, Bottari G, Oberto L et al (1995) A doubleblind-placebo controlled trial of megestrol acetate on caloric intake and nutritional status in AIDS cachexia. Fourth Congress of European Association for Palliative Care. Barcelona, December 6–9, 1995, abstracts book, pp 427–437

    Google Scholar 

  41. Rondanelli M, Solerte SB, Fioravanti M, Scevola D et al (1997) Circadian secretory pattern of growth hormone, insulin-like growth factor type I, cortisol, adrenocorticotropic hormone, thyroid-stimulating hormone, and prolactin during HIV infection. AIDS Res Hum Retroviruses 14:1243–1249

    Google Scholar 

  42. Scevola D, Bottari G, Oberto L et al (1995) Megestrol acetate (MA) and growth hormone (rHGH) as combined therapy for AIDS cachexia. Fourth Congress of European Association for Palliative Care. Barcelona, December 6–9, 1995, abstracts book, pp 438–442

    Google Scholar 

  43. Wanke C, Gerrior J, Kantaros J et al (1999) Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 13:2099–2103

    Article  PubMed  CAS  Google Scholar 

  44. Saint-Marc T, Touraine JL (1999) Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor (PI). Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, abstract 672

    Google Scholar 

  45. Walli RK, Michl GM, Bogner JR et al (1999) Effects of the PPAR-Activator troglitazone on protease inhibitor associated peripheral insulin resistance. Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, abstract 673

    Google Scholar 

  46. Carr A, Workman C, Carey D, Rogers G, Martin A, Baker D et al (2004) No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 363:429–38

    PubMed  CAS  Google Scholar 

  47. Torres R, Unger K (1999) The effect of recombinant human growth hormone on protease-inhibitor-associated fat maldistribution syndrome. Sixth Conference on Retroviruses and opportunistic Infections, Chicago, Illinois, abstract 675

    Google Scholar 

  48. Strawford A, Barbieri T, Parks E et al (1999) Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss. JAMA 281:1282–1290

    Article  PubMed  CAS  Google Scholar 

  49. Scevola D, Oberto L, Bottari G, Faggi A (1995) Lipidi e Malattie Infettive. Abstracts Book XII Congresso Nazionale ADI. Torino, 16–18/11, p 187

    Google Scholar 

  50. Scevola D, Bottari G, Oberto L, Faggi A, Venturino P (1996) Problemi nutrizionali del paziente AIDS e strategie terapeutiche. Quaderni di Cure Palliative (S1):51–64

    Google Scholar 

  51. Amsterdam EA (1997) Exercise in cardiovascular health and disease. Yorke Medical Books, New York

    Google Scholar 

  52. Smith BA, Neidig JL, Nickel JT et al (2001) Aerobic exercise: effects on parameters related to fatigue, dyspnea, weight and body composition in HIVinfected adults. AIDS 15:693–701

    PubMed  CAS  Google Scholar 

  53. Montoye HJ (1975) Physical activity and health: an epidemiologic study of an entire community. Prentice-Hall, Englewood Cliffs

    Google Scholar 

  54. Katch FI, Freedson PS, Jones CA et al (1985) Evaluation of acute cardiorespiratory responses to hydraulic resistance exercise. Med Sci Sports Exerc 17:168–173

    PubMed  CAS  Google Scholar 

  55. Crow RS, Rantahargiu PM, Prineas RJ et al (1986) Risk factors, exercise fitness and electrocardiographic response to exercise in 12,866 men at risk of symptomatic coronary heart disease. Am J Cardiol 57:1075–1082

    Article  PubMed  CAS  Google Scholar 

  56. Pollock M, Gaesser G, Butcher J et al (1998) The recommended quantity and quality of exercise for developing and maintaining cardiorespiratory and muscular fitness and flexibility in healthy adults. Med Sci Sports Exerc 30:975–991

    Google Scholar 

  57. Stringer WW, Berezovskaya M, O’Brien WA et al (1998) The effect of exercise training on aerobic fitness, immune indices, and quality of life in HIV+ patients. Med Sci Sports Exerc 30:11–16

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. D. Scevola
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Barbarini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Barbaro
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medical Pathophysiology, University “La Sapienza”, Rome, Italy

    Giuseppe Barbaro

  2. Department of Cardiology, Saint Antoine University Hospital, Assistance Publique - Hôpitaux de Paris and Université Paris VI, Paris, France

    Franck Boccara

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag Italia

About this chapter

Cite this chapter

Scevola, D., Barbarini, G., Barbaro, G. (2005). Guidelines for the Prevention of Cardiovascular Risk in HIV-Infected Patients Treated with Antiretroviral Drugs. In: Barbaro, G., Boccara, F. (eds) Cardiovascular Disease in AIDS. Springer, Milano. https://doi.org/10.1007/88-470-0358-X_14

Download citation

  • DOI: https://doi.org/10.1007/88-470-0358-X_14

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-0309-5

  • Online ISBN: 978-88-470-0358-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation